Study: Medalized KnoblaugeXtrakt lowers the blood pressure

Veröffentlicht:

Von:

In der Studie geht es um die Untersuchung der Wirkung von gealtertem Knoblauchextrakt (AGE) als Zusatzbehandlung bei Patienten mit behandelter, aber unkontrollierter Hypertonie. Die Studie verwendet eine doppelblinde, randomisierte, placebokontrollierte Studie mit 50 Patienten, die entweder AGE oder ein Placebo erhalten. Es wird festgestellt, dass AGE den systolischen Blutdruck bei Patienten mit unkontrollierter Hypertonie senkt, jedoch keine signifikanten Auswirkungen auf Patienten mit normalem Blutdruck hat. Die Studie zeigt auch, dass AGE positive Effekte auf kardiovaskuläre Ergebnisse wie Cholesterinspiegel, Homocystein, Endothelfunktion und Arteriosklerose hat. Es wird jedoch angemerkt, dass weitere Forschung zu AGE bei Herzerkrankungen und kardiovaskulären Risikofaktoren notwendig ist. Die …
The study deals with the examination of the effect of aged gnoblaue extract (AGE) as an additional treatment in patients with treated but uncontrolled hypertension. The study uses a double -blind, randomized, placebo -controlled study with 50 patients who receive either AGE or a placebo. It is determined that AGE lowers systolic blood pressure in patients with uncontrolled hypertension, but has no significant effects on patients with normal blood pressure. The study also shows that AGE has positive effects on cardiovascular results such as cholesterol, homocysteine, endothelial function and arteriosclerosis. However, it is noted that further research on AGE is necessary for heart disease and cardiovascular risk factors. The … (Symbolbild/natur.wiki)

The study deals with the examination of the effect of aged gnoblauche extract (AGE) as an additional treatment in patients with treated but uncontrolled hypertension. The study uses a double -blind, randomized, placebo -controlled study with 50 patients who receive either AGE or a placebo. It is determined that AGE lowers systolic blood pressure in patients with uncontrolled hypertension, but has no significant effects on patients with normal blood pressure. The study also shows that AGE has positive effects on cardiovascular results such as cholesterol, homocysteine, endothelial function and arteriosclerosis. However, it is noted that further research on AGE is necessary for heart disease and cardiovascular risk factors. The study has some restrictions due to the small study population, but the extent of the reduction in blood pressure by AGE could lead to a reduction in cardiovascular events.

Details of the study:

reference

ried K, Frank or, Stocks NP. Occupted knobla extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomized controlled study. Maturitas . 2010; 67 (2): 144-150.

design

This study by Ried et al. examined the effect, tolerability and acceptance of aged gnoblaue extract (AGE) as an additional treatment to existing blood pressure -lowering medication in patients with treated but uncontrolled hypertension. They used a double -blind, randomized, placebo -controlled study with 50 patients. The patients received 960 mg daily (containing 2.4 mg S-allylcystein) Age or a corresponding placebo.

most important findings

In patients with uncontrolled hypertension (SBP ≥ 140 mm Hg), the systolic blood pressure was an average of 10.2 ± 4.3 mm Hg ( p = 0.03) lower in the case of knoblain therapy compared to placebo. The changes in blood pressure between the groups were not significant in patients with an SBP <140 mmHg at the beginning of the course. AGE was well tolerated by 92 % of the participants.

Effects on the practice

This study, one of several AGE currently use, shows the potential blood pressure -lowering effect of this dietary supplement. In several previous studies, AGE was used to assess high blood pressure. This current study is the best designed and careful evaluation of the product.

The authors showed that AGE resembles the current medication of the first choice against high blood pressure.

It is interesting to determine that AGE lowered blood pressure in people with output hypertension (> 140 mm Hg) quite clearly, but not in people with normal or almost normal blood pressure values. This has a major impact on the use of the product in people without high blood pressure, because although it shows that AGE has the potential to reduce blood pressure, the dietary supplement does not trigger hypotension in people with normal blood pressure. This is similar to medication such as Ramipril, who showed a significant reduction in blood pressure in patients with high blood pressure, but showed only a low effect on blood pressure in normot -positive people. In the Heart Outcomes Prevention Evaluation Study, Ramipril reduced significantly cardiovascular events despite no significant change in blood pressure.

In addition, this increases the diverse effects of AGE on cardiovascular results. In several double-blind, randomized, controlled studies, it was shown that AGE lowers the overall cholesterol, increases high-density lipoprotein cholesterol, reduces homocysteine, improves the endothelial function and slowing the progression of arteriosclerosis. 2.3,4 It has even been shown that AGE reduces the accumulation of adipose tissue around the heart. 4 thus confirms the current study by Ried et al. the advantageous effects of this addition. In view of the popularity of complementary therapies and the motivation and compliance of the patients in treatment, 5 Further research on AGE for heart diseases and cardiovascular risk factors is required.

restrictions

The small size of the study population limits the implications somewhat. Obviously, a clinical result study would be more meaningful, but prospective studies on blood-pressure-reducing drugs, that the extent of the event reduction is directly related to the reduction in blood pressure and that greater blood pressure reductions lead to larger risk control. Blood pressure drop by 10 points with an approximately 22 percent reduction in the entire heavy cardiovascular events.